Total Payments
$2,039
2024 Payments
$17.77
Companies
23
Transactions
107
Medicare Patients
2,074
Medicare Billing
$242,610
Payment Breakdown by Category
Food & Beverage$2,039 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,039 | 107 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $357.60 | 29 | $0 (2020) |
| ABBVIE INC. | $275.80 | 16 | $0 (2024) |
| Biogen, Inc. | $273.92 | 5 | $0 (2020) |
| Celgene Corporation | $230.44 | 18 | $0 (2022) |
| EMD Serono, Inc. | $139.73 | 7 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $133.21 | 7 | $0 (2021) |
| Allergan, Inc. | $123.86 | 2 | $0 (2020) |
| Eisai Inc. | $111.71 | 1 | $0 (2023) |
| Lundbeck LLC | $100.27 | 1 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $35.74 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.77 | 1 | ABBVIE INC. ($17.77) |
| 2023 | $240.78 | 10 | ABBVIE INC. ($129.07) |
| 2022 | $107.12 | 6 | Celgene Corporation ($58.89) |
| 2021 | $355.59 | 23 | Celgene Corporation ($171.55) |
| 2020 | $374.64 | 16 | Supernus Pharmaceuticals, Inc. ($169.85) |
| 2019 | $368.35 | 17 | Biogen, Inc. ($143.31) |
| 2018 | $399.36 | 25 | Supernus Pharmaceuticals, Inc. ($120.53) |
| 2017 | $175.37 | 9 | Lundbeck LLC ($100.27) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: NEUROSCIENCE | ||||||
| 12/28/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $34.20 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2023 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $8.40 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $111.71 | General |
| Category: Neurology | ||||||
| 08/08/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: NEUROSCIENCE | ||||||
| 08/03/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.50 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.76 | General |
| Category: NEUROSCIENCE | ||||||
| 04/18/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $7.84 | General |
| Category: NEUROSCIENCE | ||||||
| 02/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.01 | General |
| Category: NEUROSCIENCE | ||||||
| 07/13/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.35 | General |
| Category: Neuroscience | ||||||
| 06/07/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $11.81 | General |
| Category: Neuroscience | ||||||
| 03/14/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: NEUROSCIENCE | ||||||
| 03/07/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.83 | General |
| Category: Neuroscience | ||||||
| 01/27/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: NEUROSCIENCE | ||||||
| 01/14/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Neuroscience | ||||||
| 11/29/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $43.12 | General |
| Category: Neuroscience | ||||||
| 10/26/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $3.19 | General |
| Category: Neuroscience | ||||||
| 10/08/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $1.96 | General |
| Category: Neuroscience | ||||||
| 10/01/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $1.48 | General |
| Category: Neuroscience | ||||||
| 09/25/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 509 | 579 | $167,658 | $59,722 |
| 2022 | 10 | 556 | 619 | $167,670 | $65,990 |
| 2021 | 9 | 510 | 572 | $148,826 | $61,650 |
| 2020 | 13 | 499 | 577 | $149,603 | $55,249 |
Total Patients
2,074
Total Services
2,347
Medicare Billing
$242,610
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 192 | 233 | $54,476 | $20,208 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 118 | 118 | $43,306 | $13,519 | 31.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 63 | $20,365 | $8,025 | 39.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 17 | 18 | $12,546 | $5,346 | 42.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $11,600 | $4,092 | 35.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 51 | $9,060 | $2,934 | 32.4% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 21 | 21 | $9,030 | $2,598 | 28.8% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 25 | 35 | $3,990 | $1,690 | 42.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 15 | $3,285 | $1,310 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 207 | 244 | $52,128 | $22,357 | 42.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 98 | 98 | $33,945 | $11,086 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 72 | 82 | $24,646 | $10,397 | 42.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 23 | 24 | $16,728 | $7,262 | 43.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 68 | $10,484 | $4,292 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $10,807 | $4,095 | 37.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 19 | 20 | $8,292 | $2,578 | 31.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 22 | 22 | $4,920 | $1,623 | 33.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 15 | 19 | $3,782 | $1,429 | 37.8% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 11 | 17 | $1,938 | $871.14 | 45.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 197 | 248 | $52,080 | $22,949 | 44.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 148 | 148 | $47,360 | $17,919 | 37.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 48 | 54 | $15,282 | $7,023 | 46.0% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2021 | 18 | 20 | $13,940 | $5,339 | 38.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 24 | 24 | $9,672 | $3,996 | 41.3% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 14 | 15 | $5,618 | $2,193 | 39.0% |
About Dr. Hani Midani, MD
Dr. Hani Midani, MD is a Neurology healthcare provider based in Castleton, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619936200.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hani Midani, MD has received a total of $2,039 in payments from pharmaceutical and medical device companies, with $17.77 received in 2024. These payments were reported across 107 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($2,039).
As a Medicare-enrolled provider, Midani has provided services to 2,074 Medicare beneficiaries, totaling 2,347 services with total Medicare billing of $242,610. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Castleton, NY
- Active Since 03/21/2006
- Last Updated 05/14/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1619936200
Products in Payments
- ZEPOSIA (Drug) $363.65
- TROKENDI XR (Drug) $349.81
- SPINRAZA (Biological) $273.92
- UBRELVY (Drug) $254.52
- Leqembi (Drug) $111.71
- QULIPTA (Drug) $105.83
- NORTHERA (Drug) $100.27
- Mavenclad (Biological) $81.47
- Rebif (Biological) $58.26
- APTIOM (Drug) $35.74
- VNS Therapy (Device) $32.56
- SPRAVATO (Drug) $31.82
- Gamunex-C (Biological) $31.60
- VRAYLAR (Drug) $24.06
- Radicava (Drug) $21.91
- Hizentra (Biological) $19.73
- AJOVY (Drug) $19.28
- EMGALITY (Drug) $15.43
- Aimovig (Biological) $15.39
- BOTOX CHRONIC MIGRAINE (Drug) $15.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.